| Course | NR 508 Advanced Pharmacology |
|---|---|
| Week | 5 |
| Paper type | Adverse effect analysis |
| Length | About 1,160 words, 3 pages |
| Format | APA 7 student paper |
| School | Chamberlain University |
| Program | MSN |
| Updated | October 2026 |
Free sample paper for NR 508 Week 5
Aching Thighs Eight Weeks Into Atorvastatin 40 mg: Placing Statin Muscle Symptoms as the Wanted Action in the Wrong Tissue, a Class Effect That Tracks Dose and a Transporter Gene, and Why Only One Report in Fifteen Is Caused by the Drug
Student Name
College of Nursing, Chamberlain University
NR 508: Advanced Pharmacology
Instructor Name
Month Day, Year
Aching Thighs Eight Weeks Into Atorvastatin 40 mg: Placing Statin Muscle Symptoms as the Wanted Action in the Wrong Tissue, a Class Effect That Tracks Dose and a Transporter Gene, and Why Only One Report in Fifteen Is Caused by the Drug
The Report
Ms. B., 61, a bookkeeper with type 2 diabetes and a calculated 10-year cardiovascular risk that meets the threshold for statin therapy, started atorvastatin 40 mg daily two months ago. She now reports a dull ache in both thighs, worse after climbing stairs, and asks whether she should stop. Her creatine kinase is normal. She takes no other new medicines. This analysis places her symptom before deciding what to do about it, because where an adverse effect sits determines whether switching drugs, lowering the dose or stopping will help.
Three Places an Effect Can Sit
An adverse effect can sit in one of three places. It can be too much of the wanted action in the intended tissue, like hypoglycemia from a diabetes drug. It can be the same action arriving in a tissue the prescription was not aimed at. Or it can be something the molecule does that has nothing to do with why it was given.
Statin muscle symptoms belong in the second place. Statins inhibit HMG-CoA reductase, the enzyme controlling a key step in cholesterol synthesis; the target tissue is the liver, where reduced synthesis increases uptake of LDL from the blood. But skeletal muscle also makes products of the same pathway, including compounds involved in cell signaling and in mitochondrial energy production, and when statins reach muscle in sufficient concentration, the same enzyme inhibition occurs there. The symptom is the wanted action in the wrong tissue. That placement predicts that it will be shared by every statin, that it will track the concentration of statin reaching muscle, and that it will resolve when the drug is withdrawn.
Does the Whole Class Do It
The best evidence comes from the Cholesterol Treatment Trialists' Collaboration, which analyzed individual participant data from 19 double-blind trials comparing statin with placebo in 123,940 people, and 4 trials comparing more with less intensive statin regimens. It found no clear evidence that the relative risk of muscle pain or weakness differed between statins (Cholesterol Treatment Trialists' Collaboration, 2022). That is what the placement predicts: an effect of the shared mechanism is a class effect.
Exposure, however, differs by molecule, and that is where individual statins separate. A variant in the SLCO1B1 gene, which encodes the transporter OATP1B1 that carries statins into the liver, reduces hepatic uptake and leaves more drug in the circulation to reach muscle. In a genomewide study of patients taking simvastatin 80 mg, the odds of myopathy were 4.5 times higher per copy of the risk allele and 16.9 times higher in people with two copies (SEARCH Collaborative Group, 2008). The class effect is shared; how much of it a patient experiences depends on how much drug reaches the muscle, which depends partly on the molecule and partly on the person.
Whether It Tracks the Dose
It does, modestly. In the collaboration's analysis, more intensive regimens, atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg daily, produced a higher relative risk of muscle pain or weakness than less intensive or moderate regimens, 1.08 against 1.03 compared with placebo (Cholesterol Treatment Trialists' Collaboration, 2022). The severe end tracks dose more steeply: the genomewide study arose from a trial of simvastatin 80 mg, the dose at which myopathy was frequent enough to study (SEARCH Collaborative Group, 2008). For Ms. B., on atorvastatin 40 mg, a high-intensity dose, dose reduction is a reasonable first step if her symptom proves related.
Does It Settle or Persist
The same analysis showed a striking time course. During the first year, statins produced a 7% relative increase in reports of muscle pain or weakness, an absolute excess of 11 events per 1,000 person-years. After the first year, there was no significant excess in first reports (Cholesterol Treatment Trialists' Collaboration, 2022). Symptoms caused by statins, in other words, appear early. A new muscle complaint in someone who has taken a statin uneventfully for five years is unlikely to be caused by it.
The time course also tells us how often the drug is actually responsible. In the placebo-controlled trials, 27.1% of people taking a statin and 26.6% of people taking placebo reported muscle pain or weakness over follow-up. The authors calculated that in the first year only about one in 15 muscle reports among people taking statins was actually caused by the statin, and concluded that more than 90% of all muscle symptoms reported by people allocated to statins were not due to the drug (Cholesterol Treatment Trialists' Collaboration, 2022). Ms. B.'s ache, eight weeks in, falls inside the window where a real effect is possible, but the odds still favor another cause.
Severity in What It Cost
For most people, the cost is discomfort, not damage. In the placebo-controlled trials, statins raised median creatine kinase by about 0.02 times the upper limit of normal, a clinically insignificant amount (Cholesterol Treatment Trialists' Collaboration, 2022). Myopathy with a high creatine kinase and rhabdomyolysis are rare and cluster where exposure is high: high doses, the transporter variant, interacting drugs or reduced kidney function. The largest cost in practice is the one hardest to see: people who stop a statin because of symptoms the drug did not cause lose the reduction in heart attacks and strokes the drug would have given them.
What Follows for Ms. B.
Her normal creatine kinase places her at the mild end. The placement, the timing and the dose together suggest a plan. Stop the atorvastatin for two to four weeks and see whether the ache resolves. If it does, restart at a lower dose, 10 or 20 mg, or try a different statin, and watch whether it returns. If the ache persists while she is off the drug, the statin was not the cause and should be restarted at full dose while another explanation, such as early osteoarthritis or deconditioning, is sought. Either way, she should not be left off statin therapy on the strength of a symptom that, most of the time, the drug does not cause.
How the plan is explained matters as much as the plan. Telling her that most muscle aches in people taking statins are not caused by the drug, and that the trial is a way of finding out whether hers is, gives her a reason to restart if the ache persists off the drug, rather than a reason to feel disbelieved.
References
Cholesterol Treatment Trialists' Collaboration. (2022). Effect of statin therapy on muscle symptoms: An individual participant data meta-analysis of large-scale, randomised, double-blind trials. The Lancet, 400(10355), 832-845. https://doi.org/10.1016/S0140-6736(22)01545-8
SEARCH Collaborative Group. (2008). SLCO1B1 variants and statin-induced myopathy: A genomewide study. New England Journal of Medicine, 359(8), 789-799. https://doi.org/10.1056/NEJMoa0801936
The Chamberlain NR 508 Week 5 instructions
The Week 5 analysis asks you to examine an adverse drug effect in a patient. Count on supplying the effect and the patient, its mechanism, whether it is a class effect, its relationship to dose and time, its severity, risk factors, management and APA. Place the effect first: too much of the wanted action, the wanted action in the wrong tissue or something unrelated to the action. Answer whether the whole class produces it, using the best evidence. Say whether it tracks dose and how it behaves over time. Judge severity by what it costs the patient. Note individual risk factors, such as genetic variants. End with a plan for this patient and how it will be explained.
How this NR 508 Week 5 example is built
The report section describes Ms. B., her cardiovascular risk, eight weeks on atorvastatin 40 mg and aching thighs with a normal creatine kinase. The placement section explains that statins inhibit HMG-CoA reductase and that muscle shares the pathway. The class section reports the collaboration's individual participant analysis and explains that exposure differs by molecule, with the SLCO1B1 variant affecting transport into the liver. The dose section reports somewhat higher excess with intensive regimens. The time section reports a 7% relative increase in the first year and little afterward, and notes that 27.1% on statins and 26.6% on placebo reported muscle symptoms. The severity section separates discomfort from damage. The plan stops atorvastatin for two to four weeks, then rechallenges.
Where the points sit in the NR 508 Week 5 rubric
Adverse effect rubrics in NR 508 usually score accurate mechanism, analysis of class versus individual effects, dose and time relationships, severity assessment, patient-specific management and APA. Answering the class question is the row this paper treats most carefully, using a large individual participant analysis. Mechanism is credited for placing the effect in the wrong tissue. Dose and time score through the modest intensity effect and the first-year pattern. Severity earns points for separating discomfort from damage with creatine kinase figures. Management is credited for a rechallenge plan and how it is explained. The CTT collaboration and the SEARCH group support the analysis.
NR 508 Week 5 help: mistakes that cost points
The analysis that names the effect and never says whether the rest of the class produces it gives away the most, because that answer shapes the management. Another loss is treating every muscle complaint as caused by the drug, ignoring the placebo arm. Students also skip dose and time, call severity "mild" without saying why or stop the drug permanently without a plan. Placement is not the same as proving causation; rechallenge helps with that. Idiosyncratic effects still have risk factors worth analyzing. Patient teaching belongs in the plan. Name the effect and drug, and an NR 508 analysis can place it before anything else.
Get a NR 508 Week 5 example written to your instructions
Send the Week 5 prompt with the agent and the effect your section named, plus any form the classroom posts, and a custom example is written to them and returned inside 24 to 48 hours, the first one free. If the assignment supplies a case around the effect, include it and the example is reasoned through that case.
More NR 508 papers and MSN samples
- NR 508 Week 1: Pharmacokinetic Property Post
- NR 508 Week 2: Dabigatran Pharmacokinetics Write-Up
- NR 508 Week 3: Calcium Channel Blocker Class Analysis
- NR 508 Week 4: Zolpidem Case Application Paper
- NR 508 Week 6: Therapeutic Failure Write-up
- NR 508 Week 7: Medication Teaching Plan
- NR 508 Week 8: Pharmacology Case Paper
- NR 510 Week 5: Business Case
- NR 506NP Week 5: NP Reimbursement and Credentialing
- NR 510F Week 5: Professional Development Plan
- NR 506 Week 5: Federal Rulemaking Process Write-Up
NR 508 Week 5 questions, answered
Is this the same as proving the drug caused it?
No, and the distinction is worth stating early in the paper. Formal causality assessment weighs timing, dose and what happened on withdrawal to reach a verdict about one event. This assignment asks something narrower and more pharmacologic: given that this agent produces this effect, explain from the drug's action why it does, and say what that implies for the class.
The effect is idiosyncratic. Is there anything to analyze?
There is, and it is often the more interesting write-up. Say plainly that the effect does not follow from the therapeutic action and does not track the dose, then name what is known about the route it does take, whether an immune response or a reactive metabolite. Ending with the honest limit of current knowledge scores better than a mechanism invented to fill the section.
Where does patient teaching fit in this week?
Usually in a short closing section, and it should be shaped by the analysis above it rather than lifted from a handout. If the effect fades, the person needs to know how long to expect it. If it does not fade and matters, they need to recognize it early. The analysis decides which of those two the closing lines say.
Where can I find a free NR 508 Week 5 sample paper?
The complete Week 5 analysis of statin muscle symptoms, with the placement, the class answer, dose and time, severity, the patient's plan and two references, can be read here.
How often does the statin actually cause the aches in the NR 508 Week 5 analysis?
Rarely: in the placebo-controlled trials 27.1% on a statin and 26.6% on placebo reported muscle symptoms, so most reported aches were not caused by the drug.